Julia Aijun Wang Sells 899 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang sold 899 shares of BeiGene stock in a transaction on Monday, June 24th. The shares were sold at an average price of $155.66, for a total value of $139,938.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BeiGene Trading Down 2.0 %

NASDAQ BGNE opened at $142.67 on Friday. The business’s 50-day moving average price is $156.93 and its two-hundred day moving average price is $159.87. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $225.23. The firm has a market capitalization of $13.67 billion, a PE ratio of -18.85 and a beta of 0.60. The company has a current ratio of 2.08, a quick ratio of 1.84 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($2.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.07) by $0.66. The company had revenue of $751.70 million for the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The firm’s revenue was up 67.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.34) EPS. On average, analysts expect that BeiGene, Ltd. will post -8.2 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BGNE shares. Bank of America decreased their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. TD Cowen boosted their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. boosted their price objective on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Finally, Sanford C. Bernstein reduced their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $251.93.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Capital International Investors raised its stake in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after buying an additional 727,556 shares during the period. First Trust Advisors LP acquired a new position in BeiGene during the 4th quarter worth approximately $39,632,000. M&G Plc acquired a new position in BeiGene during the 1st quarter worth approximately $29,649,000. Goldman Sachs Group Inc. raised its stake in shares of BeiGene by 175.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock worth $38,658,000 after purchasing an additional 136,458 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of BeiGene by 6.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after purchasing an additional 117,905 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.